Skip to main
PMN

PMN Stock Forecast & Price Target

PMN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProMIS Neurosciences is a clinical-stage biotechnology company with a unique approach to treating neurodegenerative diseases such as Alzheimer's and ALS. Their lead product candidate, PMN310, targets toxic oligomers of amyloid-beta, known to be the primary drivers of neurotoxicity in Alzheimer's. With a differentiated safety profile and strong early data, ProMIS has the potential to become a major player in this high-demand market. Additionally, the company's Phase III design and strategic considerations, as well as the potential for partnerships and strategic interest, provide further upside potential.

Bears say

ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapies for neurodegenerative diseases like AD, ALS, and MSA. While the company's innovative platform shows promise, there are significant risks involved in its development of PMN310, including competition from established players, the need for significant capital for P2b/3 programs, and potential difficulty in interpreting interim results. Additionally, the company's financials show a net loss of $11.7 million in Q2 2026, and there may be challenges in achieving statistical significance on cognitive endpoints with the upcoming 1Q27 readout. These factors contribute to a negative outlook on the stock.

PMN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProMIS Neurosciences Inc (PMN) Forecast

Analysts have given PMN a Strong Buy based on their latest research and market trends.

According to 4 analysts, PMN has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProMIS Neurosciences Inc (PMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.